Utility of a modified age-adjusted Charlson Comorbidity Index in predicting cause-specific survival among patients with gastric cancer.
Acquired Immunodeficiency Syndrome
/ epidemiology
Age Factors
Aged
Cardiovascular Diseases
/ epidemiology
Comorbidity
Dementia
/ epidemiology
Diabetes Mellitus
/ epidemiology
Female
Gastrectomy
Humans
Kidney Diseases
/ epidemiology
Liver Diseases
/ epidemiology
Male
Middle Aged
Paralysis
/ epidemiology
Prognosis
Pulmonary Disease, Chronic Obstructive
/ epidemiology
Rheumatic Diseases
/ epidemiology
Stomach Neoplasms
/ mortality
Survival Rate
Cause-specific survival
Gastric cancer
Modified age-adjusted Charlson comorbidity index
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
18
09
2020
revised:
20
01
2021
accepted:
26
01
2021
pubmed:
10
2
2021
medline:
15
12
2021
entrez:
9
2
2021
Statut:
ppublish
Résumé
The current study aimed to evaluate the ability of a modified version of the age-adjusted Charlson Comorbidity Index (mACCI) in predicting cause-specific survival (CSS) among patients with gastric cancer who underwent curative gastrectomy and compared it with the conventional ACCI. Patients who underwent gastrectomy for gastric cancer from 2007 to 2016 (n = 2885) were included. A mACCI was established by excluding scores for other malignancies, such as other cancers, leukemia, and lymphoma. After determining the optimal cutoff ACCI and mACCI values for CSS, clinicopathological factors and survival outcomes were assessed according to the ACCI and mACCI. Both ACCI and mACCI were identified as independent prognostic factors for overall survival (p < 0.001 and p < 0.001, respectively). However, only mACCI was identified as an independent prognostic factor for CSS (p < 0.001). The present study suggested that mACCI was a better indicator of CSS in patients with gastric cancer who underwent curative gastrectomy than ACCI. Our findings showed that the mACCI was a strong predictor of CSS in patients with gastric cancer who underwent curative gastrectomy. We believe that the mACCI will become a novel marker that would guide treatment decisions for patients with gastric cancer suffering from comorbidities.
Identifiants
pubmed: 33558122
pii: S0748-7983(21)00056-1
doi: 10.1016/j.ejso.2021.01.026
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2010-2015Informations de copyright
Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest MT received research grants from Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan, Ono Pharmaceutical Co., Ltd., Bristol Myers Squib Japan, and Yakult Honsha Co., Ltd. EB has received research grants from EIZO Corporation, Kanehara-Shuppan, Terumo Corporation, and EIZAI.